Zia Khould
Acute Care · Suffolk, VANPI 1033545371
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,857 of the $3,327 with a category attached, or 85.9%. It is spread thinly across 35 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,529 and has fallen 98.5% since, to $23 in 2025. Among acute care clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 137 payments — averaging $24.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$605
- Daiichi Sankyo Inc.$308
- Novartis$292
- AstraZeneca$289
- Astellas Pharma US Inc$208
- Pfizer$165
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,85786%
- Education$47014%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 26 | $605 |
| Daiichi Sankyo Inc. | 18 | $308 |
| Novartis | 12 | $292 |
| AstraZeneca | 9 | $289 |
| Astellas Pharma US Inc | 6 | $208 |
| Pfizer | 8 | $165 |
| Eisai Inc. | 8 | $154 |
| Seagen Inc. | 4 | $137 |
| Lilly USA, LLC | 2 | $118 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Array Biopharma Inc | 4 | $96 |
| Amgen | 2 | $87 |
| Merck | 3 | $71 |
| Deciphera Pharmaceuticals Inc. | 3 | $58 |
| Gilead | 3 | $54 |
| E.r. Squibb & Sons, L.L.C. | 3 | $52 |
| Bayer | 3 | $51 |
| Taiho Oncology, Inc. | 2 | $48 |
| Bristol Myers Squibb | 2 | $43 |
| Johnson & Johnson | 2 | $40 |
| Blueprint Medicines Corporation | 1 | $39 |
| Adaptive Biotechnologies Corporation | 2 | $38 |
| Coherus Oncology, Inc. | 1 | $34 |
| Stemline Therapeutics Inc. | 1 | $30 |
| Karyopharm Therapeutics Inc. | 1 | $28 |
| Tersera Therapeutics LLC | 1 | $26 |
| Tempus AI, Inc | 1 | $22 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| ADC Therapeutics America, Inc. | 1 | $18 |
| Pharmacosmos Therapeutics Inc. | 1 | $17 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
| Puma Biotechnology, Inc. | 1 | $15 |
| Exelixis Inc. | 1 | $15 |
| Incyte Corporation | 1 | $15 |
How this compares
$3,327 in reported general payments places this provider in the 90th percentile of 599 acute care providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 52 | $40,344 |
| XareltoRivaroxaban | 16 | $16,511 |
| Anastrozole | 122 | $2,605 |
| Exemestane | 17 | $1,928 |
| Letrozole | 60 | $1,112 |
| Tamoxifen Citrate | 38 | $1,102 |
| Prochlorperazine Maleate | 27 | $767 |
| Gabapentin | 31 | $325 |
| Dexamethasone | 14 | $297 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 24 | $277 |
| Hydroxyurea | 13 | $219 |
| Ondansetron Hcl | 30 | $180 |
| LoperamideLoperamide Hcl | 14 | $176 |
| Lorazepam | 14 | $96 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 11 | $75 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $165 | $40,34452 claims |
| Johnson & JohnsonXarelto | $40 | $16,51116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 599 acute care providers in Virginia.
Other acute care in Suffolk
- Scott AverySuffolk$5K
- Rachel DukeRichmond$751K
- Julia KingNorfolk$99K
- Sarah KennedyNorfolk$57K
- Sarah W ShermanNorth Chesterfield$41K
- Tamara StephensDeltaville$30K
- Debra CastnerNassawadox$28K
- Linda HartMidlothian$21K
- Mica FerlisRichmond$20K
- Corinnia WagnerFredericksburg$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.